President Donald Trump is expected to soon sign an executive order authorizing research into the benefits and risks of ibogaine, a psychedelic drug used in some countries to treat post-traumatic stress disorder (PTSD), according to an April 16 report from CBS News.
The outlet described ibogaine as a “naturally occurring compound from a shrub native to Africa” and reported that the executive order on the drug is currently being drafted. It could be signed before the end of the week.
Ibogaine has been used to mitigate symptoms of depression, anxiety, PTSD, and brain trauma, CBS News reported. However, the drug is illegal in the U.S. and is classified as a Schedule I substance along with drugs like heroin and ecstasy.
As a result, some Americans, especially veterans, have been seeking ibogaine outside the U.S. According to CBS News, countries like Mexico and several Caribbean nations often offer unregulated clinics with access to ibogaine, making them a common destination for those seeking relief from mental struggles.
Though the executive order reportedly would not change ibogaine’s classification, it is intended to promote further research on the drug’s effectiveness for PTSD and brain trauma treatments through federal funding. The Trump administration is particularly interested in researching the drug to determine whether it could help veterans.
CBS News reported, “Trump officials said the medical research into ibogaine is in an early phase, but the administration wants to help determine whether it's ‘snake oil’ or a legitimate treatment.”
According to the outlet, small preliminary studies have shown the drug can reduce PTSD and mental trauma in veterans, but early research has found the drug can cause fatal heart rhythm disturbances. More extensive research, including advanced clinical tests, will be needed before ibogaine can be considered for medical use.